Table 1.
Antiproliferative activities against esophageal cancer cell lines
| Compd. | IC50 (μM) |
||||
|---|---|---|---|---|---|
| KYSE-150 | KYSE-270 | TE-1 | KYSE-510 | EC109 | |
| B | >20 | >20 | >20 | >20 | >20 |
| C1 | 11.37 ± 0.69 | 12.26 ± 0.80 | 14.33 ± 0.68 | 13.91 ± 0.37 | 18.65 ± 0.92 |
| C2 | 14.60 ± 0.16 | 9.34 ± 0.29 | 10.27 ± 0.91 | 9.34 ± 0.21 | 15.22 ± 0.36 |
| C3 | 10.49 ± 0.38 | 14.16 ± 0.90 | 17.31 ± 0.68 | 11.07 ± 0.16 | 6.34 ± 0.11 |
| C4 | 6.55 ± 0.20 | 7.83 ± 0.19 | 9.17 ± 0.09 | 8.12 ± 0.72 | 5.29 ± 0.28 |
| C5 | 4.04 ± 0.16 | 2.04 ± 0.57 | 3.09 ± 0.10 | 5.07 ± 0.46 | 3.18 ± 0.27 |
| C6 | 2.17 ± 0.59 | 1.35 ± 0.05 | 0.95 ± 0.07 | 4.15 ± 0.13 | 0.83 ± 0.04 |
| C7 | 6.21 ± 0.14 | 5.29 ± 0.20 | 6.19 ± 0.25 | 9.22 ± 0.14 | 5.87 ± 0.27 |
| C8 | 3.59 ± 0.08 | 2.04 ± 0.21 | 1.76 ± 0.09 | 5.13 ± 0.17 | 1.66 ± 0.04 |
| 5-Fluorouracil | 17.39 ± 0.21 | 13.05 ± 0.62 | 7.73 ± 0.18 | 13.02 ± 0.70 | 9.62 ± 0.35 |